SCHEMBL7678940

SCHEMBL7678940

CCCCCC1CCOC(C)O1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.62
ALDH1A1 P00352 2/20 0.50
CYP1A2 P05177 3/20 0.40
TDP1 Q9NUW8 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.37
PRKD3 O94806 2/20 0.35
PRKCG P05129 2/20 0.35
PRKCB P05771 2/20 0.35
PRKCA P17252 2/20 0.35
PRKCH P24723 2/20 0.35
PRKCI P41743 2/20 0.35
PRKCE Q02156 2/20 0.35
PRKCQ Q04759 2/20 0.35
PRKCZ Q05513 2/20 0.35
PRKCD Q05655 2/20 0.35
PRKD1 Q15139 2/20 0.35
RAD52 P43351 1/20 0.34
CHRM2 P08172 1/20 0.33
CHRM5 P08912 1/20 0.33
CHRM1 P11229 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7764571 0.98 EPHX1 (0.60) EPHX1ALDH1A1CYP1A2TDP1SMN1; SMN2
SCHEMBL2997425 0.81 EPHX1 (0.62) EPHX1ALDH1A1PRKD3PRKCGPRKCB
SCHEMBL7674359 0.79 EPHX1 (0.60) EPHX1ALDH1A1CYP1A2PRKD3PRKCG
SCHEMBL7678863 0.79 EPHX1 (0.60) EPHX1ALDH1A1CYP1A2TDP1PRKD3
SCHEMBL9899314 0.79
SCHEMBL9113344 0.78 ALDH1A1 (0.69) EPHX1ALDH1A1CYP1A2TDP1SMN1; SMN2
SCHEMBL25304106 0.77 EPHX1 (1.00) EPHX1ALDH1A1CYP1A2TDP1SMN1; SMN2
SCHEMBL2731115 0.77 EPHX1 (1.00) EPHX1ALDH1A1CYP1A2TDP1SMN1; SMN2
SCHEMBL25303980 0.77 EPHX1 (1.00) EPHX1ALDH1A1CYP1A2TDP1SMN1; SMN2
SCHEMBL22454917 0.77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240410055-A1 METHOD AND FORMULATION FOR PREPARING OPTICAL METAL OXIDE LAYERS MERCK PATENT GMBH (DE) 2024-12-12 US disclosed
US-20240277012-A1 DUPLICATE BEVERAGE WANG JIE (US) 2024-08-22 US disclosed
CN-118076767-A Method and formulation for producing an optical metal oxide layer 默克专利有限公司 2024-05-24 CN disclosed
US-20240108040-A1 HIGH INTENSITY SWEETENERS FIRMENICH INCORPORATED (US) 2024-04-04 US disclosed
US-11758933-B2 High intensity sweeteners FIRMENICH INCORPORATED (US) 2023-09-19 US disclosed
WO-2023057401-A1 METHOD AND FORMULATION FOR PREPARING OPTICAL METAL OXIDE LAYERS MERCK PATENT GMBH (DE) 2023-04-13 WO disclosed
EP-3368542-B1 HIGH INTENSITY SWEETENERS FIRMENICH INCORPORATED (US) 2022-06-22 EP disclosed
US-11357246-B2 High intensity sweeteners FIRMENICH INCORPORATED (US) 2022-06-14 US disclosed
US-6384243-B1 ENZYMATIC CONVERSION OF UNSATURATED FATTY ACID; CIDER APPLE; LINOLEIC ACID Ricard, Pernod (FR) 2002-05-07 US disclosed
EP-1021433-B1 METHOD FOR PRODUCING NATURAL DIOL-1,3 DERIVATIVES AND CORRESPONDING NATURAL 1,3-DIOXANE DERIVATIVES PERNOD RICARD (FR) 2001-11-14 EP disclosed
EP-0927176-B1 1,3-DIOXANE DERIVATIVES, SYNTHESIS METHOD THEREFOR AND AROMATIC COMPOSITIONS CONTAINING SAME PERNOD RICARD (FR) 2001-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240108040-A1 HIGH INTENSITY SWEETENERS TAS2R40, TAS2R60, TAS1R1 EPHX1 3026/4885ALDH1A1 978/4885CYP1A2 4564/4885
US-11357246-B2 High intensity sweeteners TAS2R40, TAS2R60, TAS1R1 EPHX1 3026/4885ALDH1A1 978/4885CYP1A2 4564/4885
US-11758933-B2 High intensity sweeteners TAS2R40, TAS2R60, TAS1R1 EPHX1 3026/4885ALDH1A1 978/4885CYP1A2 4564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.